Iodine kinetic studies during amiodarone treatment

• Published in: The journal of clinical endocrinology and metabolism Vol. 62; no. 3; p. 563
• Main Authors: Rao, R H, McCready, V R, Spathis, G S
• Format: Journal Article
• Language: English
• Published: United States 01.03.1986
• Subjects: Adult; Aged; Amiodarone - analogs & derivatives; Amiodarone - metabolism; Benzofurans - metabolism; Biological Availability; Female; Humans; Iodides - blood; Iodides - metabolism; Iodides - urine; Iodine - metabolism; Kinetics; Male; Mathematics; Metabolic Clearance Rate; Middle Aged; Thyroid Gland - metabolism; Thyroid Hormones - blood
• ISSN: 0021-972X
• DOI: 10.1210/jcem-62-3-563

Iodine kinetic studies were performed serially in 15 patients taking 300 mg amiodarone/day for 6 months to assess the biological significance of the high iodine content of the drug. Urinary inorganic iodide excretion increased from 0.25 +/- 0.03 (+/- SE) mumol/mmol creatinine before treatment to over 7 mumol/mmol during therapy. Thyroid iodide clearance fell from 5.93 +/- 0.82 ml/min to less than 0.5 ml/min, while plasma inorganic iodide rose from 0.05 +/- 0.01 mumol/liter to approximately 2.2 mumol/liter during treatment. Thyroid absolute iodide uptake rose from 16.3 +/- 2.7 to 54.6 +/- 5.7 nmol/h after 6 weeks of therapy (P less than 0.001). Thereafter, it progressively declined, but it was still significantly elevated (32.0 +/- 4.3 nmol/h) after 24 weeks (P less than 0.01). The calculated daily excretion of inorganic iodide rose to over 80 mumol during the study, accounting for about 10% of amiodarone iodine. During this time, the patients all had the characteristic plasma thyroid hormone changes associated with amiodarone therapy, i.e. increased T4, free T4, and rT3 and decreased T3, while remaining clinically euthyroid. The massive increase in available inorganic iodide during amiodarone treatment is probably responsible for the induction of both the hypothyroidism and the thyrotoxicosis that can occur in patients receiving the drug.